The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-Cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)

P. Cahn, K. Ruxrungtham, B. Gazzard, K. van Norren, R.S. Diaz, A. Gori, D.P. Kotler, A. Vriesema, N.A. Georgiou, J. Garssen, M. Clerici, J.M.A. Lange

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)

Abstract

Background The immunomodulatory nutritional product NR100157 was developed for human immunodeficiency virus (HIV)–infected individuals. We hypothesized that targeting the compromised gastrointestinal tract of HIV-infected individuals would result in systemic immunological benefits. Methods In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1–positive adults not on antiretroviral therapy, with CD4+ T-cell counts
Original languageEnglish
Pages (from-to)139-146
JournalClinical infectious diseases
Volume57
Issue number1
DOIs
Publication statusPublished - 2013

Keywords

  • virus type-1 infection
  • viral load
  • bovine colostrum
  • pathogenesis
  • restoration
  • enteropathy
  • prebiotics
  • depletion
  • survival
  • mucosa

Fingerprint Dive into the research topics of 'The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-Cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)'. Together they form a unique fingerprint.

Cite this